The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

Eli Lilly has unveiled a $27bn investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at President Donald ...

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...